Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia

Newcombe, A. A., Gibson, B. E.S. and Keeshan, K. (2018) Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia. Experimental Hematology, 63, pp. 1-11. (doi:10.1016/j.exphem.2018.03.008) (PMID:29608923)

[img]
Preview
Text
159845.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

719kB

Abstract

There is a desperate need for new and effective therapeutic approaches for AML in both children and adults. Epigenetic aberrations are common in adult AML, and many novel epigenetic compounds are in clinical development that may improve patient outcomes. Mutations in epigenetic regulators occur less frequently in AML in children compared to adults. However, investigating the potential benefits of epigenetic therapy in paediatric AML is an important issue that will be discussed in this review.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Newcombe, Ashley and Gibson, Professor Brenda and Keeshan, Dr Karen
Authors: Newcombe, A. A., Gibson, B. E.S., and Keeshan, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Experimental Hematology
Publisher:Elsevier
ISSN:0301-472X
ISSN (Online):1873-2399
Published Online:30 March 2018
Copyright Holders:Copyright © 2018 ISEH – Society for Hematology and Stem Cells
First Published:First published in Experimental Hematology 63: 1-11
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record